EP3843747A4 - Taurolidine treatment for myc-expressing tumors in mammalian bodies - Google Patents
Taurolidine treatment for myc-expressing tumors in mammalian bodies Download PDFInfo
- Publication number
- EP3843747A4 EP3843747A4 EP19854097.3A EP19854097A EP3843747A4 EP 3843747 A4 EP3843747 A4 EP 3843747A4 EP 19854097 A EP19854097 A EP 19854097A EP 3843747 A4 EP3843747 A4 EP 3843747A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- myc
- expressing tumors
- mammalian bodies
- taurolidine treatment
- taurolidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862725650P | 2018-08-31 | 2018-08-31 | |
PCT/US2019/049266 WO2020047530A1 (en) | 2018-08-31 | 2019-09-03 | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3843747A1 EP3843747A1 (en) | 2021-07-07 |
EP3843747A4 true EP3843747A4 (en) | 2022-12-28 |
Family
ID=69643283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19854097.3A Pending EP3843747A4 (en) | 2018-08-31 | 2019-09-03 | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3843747A4 (en) |
JP (1) | JP2021535167A (en) |
KR (1) | KR20210054544A (en) |
CN (1) | CN113226325A (en) |
AU (1) | AU2019331913A1 (en) |
CA (1) | CA3111100A1 (en) |
WO (1) | WO2020047530A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001039762A2 (en) * | 1999-12-06 | 2001-06-07 | Rhode Island Hospital, A Lifespan Partner | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
US20040176360A1 (en) * | 1999-12-06 | 2004-09-09 | Paul Calabresi | Use of taurolidine to treat tumors |
WO2007077528A1 (en) * | 2006-01-06 | 2007-07-12 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam |
US20080171738A1 (en) * | 2001-04-03 | 2008-07-17 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of Breast Cancer |
WO2017158570A1 (en) * | 2016-03-18 | 2017-09-21 | Geistlich Pharma Ag | Method of treating triple negative breast cancer |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9005856D0 (en) * | 1990-03-15 | 1990-05-09 | Geistlich Soehne Ag | Compositions |
US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
US7151099B2 (en) * | 1998-07-31 | 2006-12-19 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases |
GB9716219D0 (en) * | 1997-07-31 | 1997-10-08 | Geistlich Soehne Ag | Prevention of metastases |
US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
JP5043294B2 (en) * | 2003-09-29 | 2012-10-10 | エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー | How to treat mesothelioma |
US7964571B2 (en) * | 2004-12-09 | 2011-06-21 | Egen, Inc. | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
WO2007020509A1 (en) * | 2005-08-15 | 2007-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth |
JP5926243B2 (en) * | 2010-06-01 | 2016-05-25 | ガイストリヒ・ファーマ・アクチェンゲゼルシャフトGeistlich Pharma Ag | Methods and compositions for oral drug therapy |
CN108778339A (en) * | 2016-01-11 | 2018-11-09 | 科医公司 | Therapeutic nano particle for treating neuroblastoma and other cancers |
-
2019
- 2019-09-03 CA CA3111100A patent/CA3111100A1/en active Pending
- 2019-09-03 CN CN201980072806.2A patent/CN113226325A/en active Pending
- 2019-09-03 AU AU2019331913A patent/AU2019331913A1/en active Pending
- 2019-09-03 EP EP19854097.3A patent/EP3843747A4/en active Pending
- 2019-09-03 WO PCT/US2019/049266 patent/WO2020047530A1/en unknown
- 2019-09-03 JP JP2021511591A patent/JP2021535167A/en active Pending
- 2019-09-03 KR KR1020217009412A patent/KR20210054544A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001039762A2 (en) * | 1999-12-06 | 2001-06-07 | Rhode Island Hospital, A Lifespan Partner | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
US20040176360A1 (en) * | 1999-12-06 | 2004-09-09 | Paul Calabresi | Use of taurolidine to treat tumors |
US20080171738A1 (en) * | 2001-04-03 | 2008-07-17 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of Breast Cancer |
WO2007077528A1 (en) * | 2006-01-06 | 2007-07-12 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam |
WO2017158570A1 (en) * | 2016-03-18 | 2017-09-21 | Geistlich Pharma Ag | Method of treating triple negative breast cancer |
Non-Patent Citations (8)
Title |
---|
ANGERER JÜRGEN ET AL: "Opinion on methylene glycol", 26 June 2012 (2012-06-26), pages 1 - 14, XP055982131, Retrieved from the Internet <URL:chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_097.pdf> [retrieved on 20221116] * |
ANONYMOUS: "Cormedix Inc. announces agreement with nanoproteagen for its proprietary nanoparticle technology, Nanopro TM, in combination with CRMD-005 for pediatric neuroblastoma", INTERNET CITATION, 11 May 2016 (2016-05-11), XP002792142, Retrieved from the Internet <URL:http://www.cormedix.com/cormedix-inc-announces-agreement-with-nanoproteagen-for-its-proprietary-nanoparticle-technology-nanopro-in-combination-with-crmd-005-for-pediatric-neuroblastoma-2/> [retrieved on 20190617] * |
JONES D S ET AL: "A study of the stability of taurolidine in plasma and protein-free serum", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 64, no. 2-3, 30 October 1990 (1990-10-30), pages R1 - R4, XP023736496, ISSN: 0378-5173, [retrieved on 19901030], DOI: 10.1016/0378-5173(90)90278-C * |
KEVIN MARLEY ET AL: "Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, BIOMED CENTRAL LTD, LONDON UK, vol. 32, no. 1, 11 October 2013 (2013-10-11), pages 74, XP021165358, ISSN: 1756-9966, DOI: 10.1186/1756-9966-32-74 * |
LUO JUHUA ET AL: "Association between Six Environmental Chemicals and Lung Cancer Incidence in the United States", JOURNAL OF ENVIRONMENTAL AND PUBLIC HEALTH, vol. 2011, no. 9, 1 January 2011 (2011-01-01), pages 1 - 9, XP055982102, ISSN: 1687-9805, Retrieved from the Internet <URL:https://downloads.hindawi.com/journals/jeph/2011/463701.pdf> DOI: 10.1155/2011/463701 * |
MÖHLER HANS ET AL: "Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (Review)", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 45, no. 4, 1 October 2014 (2014-10-01), GR, pages 1329 - 1336, XP055945228, ISSN: 1019-6439, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151817/pdf/ijo-45-04-1329.pdf> DOI: 10.3892/ijo.2014.2566 * |
See also references of WO2020047530A1 * |
STENDEL RUEDIGER ET AL: "Pharmacokinetics of Taurolidine following Repeated Intravenous Infusions Measured by HPLC-ESI-MS/MS of the Derivatives Taurultame and Taurinamide in Glioblastoma Patients :", CLINICAL PHARMACOKINETICS., vol. 46, no. 6, 1 January 2007 (2007-01-01), NZ, pages 513 - 524, XP055945305, ISSN: 0312-5963, Retrieved from the Internet <URL:http://dx.doi.org/10.2165/00003088-200746060-00005> DOI: 10.2165/00003088-200746060-00005 * |
Also Published As
Publication number | Publication date |
---|---|
CN113226325A (en) | 2021-08-06 |
AU2019331913A1 (en) | 2021-04-29 |
WO2020047530A1 (en) | 2020-03-05 |
CA3111100A1 (en) | 2020-03-05 |
EP3843747A1 (en) | 2021-07-07 |
KR20210054544A (en) | 2021-05-13 |
JP2021535167A (en) | 2021-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3873530A4 (en) | Therapeutic methods | |
EP4010080C0 (en) | Heterocyclic compounds for use in the treatment of cancer | |
EP3666888A4 (en) | Method for activating t cells for cancer treatment | |
EP3658139A4 (en) | Methods for treating liver diseases | |
EP3801563A4 (en) | Materials and methods for treating cancer | |
EP3893883A4 (en) | Methods for the treatment of depression | |
EP3781188A4 (en) | Adoptive cellular therapy | |
EP3823653A4 (en) | Programmable bacteria for the treatment of cancer | |
EP3766497A4 (en) | Drug for treating cough | |
EP3802802A4 (en) | Cell therapy | |
EP3400013A4 (en) | Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment | |
EP3866804A4 (en) | Combinations for immune-modulation in cancer treatment | |
EP3870104A4 (en) | Methods and materials for treating cancer | |
EP3808409A4 (en) | Radiotherapy apparatus | |
EP3873205A4 (en) | Materials and methods for treating cancer | |
EP3713576A4 (en) | Methods for cancer therapy | |
EP3905942A4 (en) | Formulation for use in treating osteoarthritis | |
EP3891070A4 (en) | Skyport for estol | |
EP3856207A4 (en) | Treatment methods | |
EP3383321A4 (en) | Tegmen plate prosthesis and methods for manufacturing the same | |
EP3897602A4 (en) | Pharmaceutical combinations for the treatment of cancer | |
EP3880216A4 (en) | Methods for treating cancer with manufactured t cells | |
EP3894561A4 (en) | Methods for treating cancer | |
EP3856241A4 (en) | Treatment methods | |
EP3831410A4 (en) | Pharmaceutical composition for treating b cell lybphoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20210326 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/50 20060101ALI20220727BHEP Ipc: A61K 38/19 20060101ALI20220727BHEP Ipc: A61K 31/549 20060101AFI20220727BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20221128 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/50 20060101ALI20221122BHEP Ipc: A61K 38/19 20060101ALI20221122BHEP Ipc: A61K 31/549 20060101AFI20221122BHEP |